Literature DB >> 7670136

The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma.

A Maki1, H Diwakaran, B Redman, S al-Asfar, G R Pettit, R M Mohammad, A al-Katib.   

Abstract

The effects of dolastatin 10 (Dol10) and dolastatin 15 (Dol15) alone, and after treatment with bryostatin 1 (Bryo1), on human diffuse large cell lymphoma cell line (WSU-DLCL2) were studied. At a concentration of 1.0 ng/ml Dol10 and Dol15 showed significant growth inhibition (p < 0.05). This inhibition was intensified when the cells were pretreated for 24 h with 200 nM Bryo1. Bryo1, Dol10 and Dol15 induced apoptosis which was seen on morphological examination, by flow cytometry and DNA fragmentation on agarose gel electrophoresis. Cells pretreated with Bryo1 and then exposed to Dol10 showed an increase in apoptosis compared with cells that were treated with the Dol10, Dol15 alone. Immunocytochemistry revealed that WSU-DLCL2 cells express the bcl-2 oncoprotein constitutively. bcl-2 expression was decreased when cells were treated with Bryo1, Dol10 or Dol15 and abolished with the Bryo1/Dol10 combination. WSU-DLCL2 cells were negative for p53 protein expression, upon treatment with Bryo1 or Dol10, the expression of p53 was weak and moderate with the Bryo1/Dol10 combination. The inverse correlation between bcl-2 and p53 oncoprotein expression seems to be related to induction of apoptosis in this lymphoma cell line.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7670136     DOI: 10.1097/00001813-199506000-00005

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  11 in total

1.  Molecular Events as Targets of Anticancer Drug Therapy.

Authors:  Adorján Aszalós; Sándor Eckhardt
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

2.  Bioactive substances with anti-neoplastic efficacy from marine invertebrates: Bryozoa, Mollusca, Echinodermata and Urochordata.

Authors:  Peter Sima; Vaclav Vetvicka
Journal:  World J Clin Oncol       Date:  2011-11-10

Review 3.  Bioactive Compounds from Marine Heterobranchs.

Authors:  Conxita Avila; Carlos Angulo-Preckler
Journal:  Mar Drugs       Date:  2020-12-21       Impact factor: 5.118

Review 4.  New drug development in non-Hodgkin lymphomas.

Authors:  B D Cheson
Journal:  Curr Oncol Rep       Date:  2001-05       Impact factor: 5.075

5.  Phase II study of bryostatin 1 in patients with relapsed multiple myeloma.

Authors:  M L Varterasian; P A Pemberton; K Hulburd; D H Rodriguez; A Murgo; A M Al-Katib
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

Review 6.  Protein kinase C targeting in antineoplastic treatment strategies.

Authors:  W D Jarvis; S Grant
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

7.  Specific activities of dolastatin 10 and peptide derivatives against Cryptococcus neoformans.

Authors:  R K Pettit; G R Pettit; K C Hazen
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 8.  Antitumor peptides from marine organisms.

Authors:  Lan-Hong Zheng; Yue-Jun Wang; Jun Sheng; Fang Wang; Yuan Zheng; Xiu-Kun Lin; Mi Sun
Journal:  Mar Drugs       Date:  2011-10-10       Impact factor: 6.085

9.  A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.

Authors:  F H Blackhall; M Ranson; J A Radford; B W Hancock; M Soukop; A T McGown; A Robbins; G Halbert; G C Jayson
Journal:  Br J Cancer       Date:  2001-02       Impact factor: 7.640

Review 10.  An Updated Review on Marine Anticancer Compounds: The Use of Virtual Screening for the Discovery of Small-Molecule Cancer Drugs.

Authors:  Verónica Ruiz-Torres; Jose Antonio Encinar; María Herranz-López; Almudena Pérez-Sánchez; Vicente Galiano; Enrique Barrajón-Catalán; Vicente Micol
Journal:  Molecules       Date:  2017-06-23       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.